Plasma homocysteine in subjects with familial combined hyperlipidemia

M. J. Veerkamp, J. De Graaf, M. Den Heijer, H. J. Blom, A. F.H. Stalenhoef

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)

Abstract

Familial combined hyperlipidemia (FCH) is characterised by hypercholesterolemia and/or hypertriglyceridemia and associated with an increased risk of cardiovascular disease (CVD). The plasma lipid and lipoprotein levels in subjects with FCH are relatively moderately elevated and do not fully explain the increased risk of CVD. Hyperhomocysteinemia is a disorder of methionine metabolism and also a well-known independent risk factor for CVD. We investigated whether subjects with FCH have higher plasma homocysteine concentrations than controls, and whether homocysteine contributes to the increased risk of CVD in FCH. Furthermore we evaluated whether parameters of lipid and lipoprotein metabolism and/or insulin resistance are associated with the homocysteine level. In total 667 subjects, including 161 subjects with FCH, 109 spouses who referenced as control group and 397 normolipidemic relatives were studied. FCH was defined by the presence of plasma total cholesterol and/or triglyceride levels above the 90th percentile adjusted for age and gender. The mean homocysteine concentration of the FCH group did not significantly differ from the control group. The risk for CVD due to hyperhomocysteinemia in subjects with FCH was not higher than in subjects without FCH. No associations were observed between plasma homocysteine concentration and plasma lipid and lipoprotein levels, including small dense low density lipoprotein, nor between homocysteine concentration and insulin resistance.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalAtherosclerosis
Volume166
Issue number1
DOIs
Publication statusPublished - 1 Jan 2003

Keywords

  • Cardiovascular disease
  • Familial combined hyperlipidemia
  • Homocysteine

Cite this